Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers befo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific Reports Jg. 12; H. 1; S. 193 - 9
Hauptverfasser:	Yoo, Hae Won, Park, Jun Yong, Kim, Sang Gyune, Jung, Young Kul, Lee, Sae Hwan, Kim, Moon Young, Jun, Dae Won, Jang, Jae Young, Lee, Jin Woo, Kwon, Oh Sang
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Springer Science and Business Media LLC 07.01.2022 Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Schlagworte:	692/4020/4021 692/699/1503/1607/1605 Administration Administration, Oral Aged Antiviral Agents Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral drugs Carbamates Carbamates - administration & dosage Carcinoma Carcinoma, Hepatocellular Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - prevention & control Carcinoma, Hepatocellular - virology Chronic / diagnosis Chronic / drug therapy Chronic / epidemiology Chronic / virology Clinical trials Combination Drug Therapy Drug Therapy, Combination Elasticity Imaging Techniques Eradication Female Fibrosis Hepatitis C Hepatitis C, Chronic Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - epidemiology Hepatitis C, Chronic - virology Hepatocellular / diagnosis Hepatocellular / epidemiology Hepatocellular / prevention & control Hepatocellular / virology Hepatocellular carcinoma Humanities and Social Sciences Humans Imidazoles Imidazoles - administration & dosage Incidence Interferon Interferons Interferons - administration & dosage Isoquinolines Isoquinolines - administration & dosage Liver Liver cancer Liver Cirrhosis Liver Cirrhosis - diagnostic imaging Liver Cirrhosis - drug therapy Liver Cirrhosis - epidemiology Liver Cirrhosis - virology Liver Neoplasms Liver Neoplasms - diagnosis Liver Neoplasms - epidemiology Liver Neoplasms - prevention & control Liver Neoplasms - virology Male Medicine Middle Aged multidisciplinary Oral Patients Prospective Studies Pyrrolidines Pyrrolidines - administration & dosage Q R Retrospective Studies Ribavirin Ribavirin - administration & dosage Science Science (multidisciplinary) Seoul Sulfonamides Sulfonamides - administration & dosage Sustained Virologic Response Time Factors Treatment Outcome Valine Valine - administration & dosage Valine - analogs & derivatives Seoul
ISSN:	2045-2322, 2045-2322
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN. Clinical trials registration: ClinicalTrials.gov (NCT02865369).
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-021-03272-1